Keywords
metformin
prothrombin time (PT)
activated thromboplastin time (APTT)
T2DM patients
Abstract
This study is aimed at investigating the relationship between treatment modality, glycemic control and blood homeostasis as represented by prothrombin time (PT) and activated thromboplastin time (APTT) in T2DM patients. Sixty-four type 2 diabetic patients (40 males and 24 females) on metformin or insulin or both for not less than six months of ages between 20 and 75 years were selected during their visit to Diabetes Endocrine and Metabolism Centers in two General Hospitals in Basra. Socioeconomic characteristics and treatment plans were recorded. Glycated haemoglobin (HbA1c), lipid profiles and hematological parameters measured in blood samples were taken. Lower mean HbA1c (p = 0.0383) was found in patients on metformin alone, higher percentage of hemoglobin was found in patients on insulin treatment, and higher levels of LDL (P = 0.0018) and HDL (P = 0.0241) in patients on metformin and insulin. Treatment manner had no effect on mean PT or APTT, however, there was a significant inverse correlation of PT with LDL (P = 0.0042), and a direct correlation of APTT with HbA1c (p = 0.0209) and an inverse correlation of APTT with platelets count (P = 0.0324) in patients on insulin treatment. In addition, there was a significant direct correlation of APTT with triglycerides (TG) (P = 0.0069) in patients on metformin treatment. In conclusion, lower mean of HbA1c was found only in patients receiving metformin drug alone, higher Hb percentage were found in patients treated with insulin alone, higher LDL and higher HDL levels were found in patients treated with both metformin and insulin for at least six months. Treatment manner had no effect on mean PT or APTT and further studies are needed to bring about understanding of diabetic control and blood homeostasis.References
1. da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, Guariguata L, Seuring T, Zhang P, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract. 2016;117:48-54.
2. Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res. 2012;129(3):371-7.
3. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 2003;25(12):2991-3026.
4. Markowicz-Piasecka M, Huttunen K, Mateusiak L, Mikiciuk-Olasik E, Sikora J. Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics. Curr Pharm Des. 2017;23(17):2532-50.
5. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC, Goto S, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892-9.
6. Ambelu YA, Shiferaw MB, Abebe M, Enawgaw B. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. J Diabetes Metab Disord. 2018;17(2):117-21.
7. American Diabetes Association. Executive summary: Standards of medical care in diabetes - 2014. Diabetes Care. 2014;37:S5.
8. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. AJM. 2007;120(9):S12-7.
9. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-81.
10. Kumar A, Shanmugasundaram P. Development of a Validated Questionnaire to Assess Attitude of Patient to-wards Self-Management among uncontrolled diabetic population in Tamil Nadu. IJRPS. 2019;10(2):1089-95.
11. Johny SA, Anupriya AP, John O, Surekha G, Paarakh PM. Evaluation of pharmacoeconomics, medication adherence and quality of life in type 2 diabetes mellitus patients. IJRPS. 2017;8(3):315-20.
12. Hasslacher C, Collenberg E, Möcks J. Effect of insulin analogs on the decline of hemoglobin in diabetic patients with nephropathy. Exp Clin Endocrinol Diabetes. 2010;118(06):341-5.
13. Teliga-Czajkowska J, Sienko J, Zareba-Szczudlik J, Malinowska-Polubiec A, Romejko-Wolniewicz E, Czajkowski K. Influence of glycemic control on coagulation and lipid metabolism in pregnancies complicated by pregestational and gestational diabetes mellitus. Adv Biomed. 2019:81-8.
14. Practice Committee of the American Society for Reproductive Medicine. Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. Fertility and sterility. 2017;108(3):426-41.
15. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(01):27-31.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2021 Authors